Mercado global de terapia contra o cancro dirigida a pequenas moléculas – Tendências e previsões do setor para 2030

Análise e tamanho do mercado de terapia contra o cancro dirigida a moléculas pequenas

Os rápidos avanços na descoberta e desenvolvimento de medicamentos levaram à identificação e ao desenvolvimento de uma vasta gama de terapias dirigidas a pequenas moléculas. Estas terapias têm como alvo moléculas ou vias específicas envolvidas no crescimento e progressão do cancro, oferecendo maior eficácia e efeitos secundários reduzidos em comparação com a quimioterapia tradicional.

A Data Bridge Market Research analisa que o mercado global de terapia contra o cancro dirigido a pequenas moléculas, que foi de 75.960,00 milhões de dólares em 2022, subiria para 124.772,24 milhões de dólares até 2030 e deverá passar por um CAGR de 6 ,4% durante o período de previsão. As “Pequenas Moléculas” dominam o segmento do mercado global de terapia contra o cancro dirigida a pequenas moléculas devido ao crescente investimento na saúde. Além dos insights sobre cenários de mercado, tais como valor de mercado, taxa de crescimento, segmentação, cobertura geográfica e grandes players, os relatórios de mercado com curadoria da Data Bridge Market Research incluem também análise especializada aprofundada, epidemiologia de pacientes, análise de pipeline, análise de preços, e quadro regulamentar.

Âmbito e segmentação do mercado de terapia contra o cancro dirigida a pequenas moléculas

Definição de mercado

O mercado global de terapia contra o cancro direcionado para pequenas moléculas é o segmento da indústria farmacêutica focado no desenvolvimento, fabrico e comercialização de medicamentos de pequenas moléculas especificamente concebidos para atingir e inibir moléculas ou vias específicas envolvidas no crescimento e progressão do cancro. Estes medicamentos, também conhecidos como terapias dirigidas ou medicamentos direcionados molecularmente, são concebidos para interferir em processos celulares específicos que contribuem para o crescimento, sobrevivência e metástase do tumor.

Ao contrário dos medicamentos quimioterápicos tradicionais que podem afetar as células cancerígenas e as células normais, as terapias dirigidas a moléculas pequenas têm como alvo as células cancerígenas, ao mesmo tempo que minimizam os danos nas células saudáveis ​​seletivamente. Funcionam interagindo com alvos moleculares específicos, como proteínas, enzimas ou vias de sinalização, que desempenham um papel crítico no desenvolvimento e progressão tumoral.

Dinâmica global do mercado de terapia contra o cancro dirigida a pequenas moléculas

Motoristas

• Aumento da incidência de cancro

A crescente prevalência do cancro em todo o mundo é um dos principais impulsionadores do mercado da terapia contra o cancro dirigida a pequenas moléculas. À medida que o fardo global do cancro aumenta, há uma necessidade crescente de opções de tratamento mais eficazes e personalizadas.

• Crescente procura por medicina personalizada

Existe uma procura crescente por medicina personalizada no tratamento do cancro, onde as terapias são adaptadas ao perfil molecular específico de um indivíduo. As terapias dirigidas a pequenas moléculas oferecem potencial para abordagens de tratamento mais precisas e personalizadas, abordando as características únicas do cancro de cada paciente.

Oportunidade

• Desenvolvimento de biomarcadores

Os biomarcadores desempenham um papel crucial na seleção dos doentes e na monitorização da resposta ao tratamento. O desenvolvimento de biomarcadores fiáveis ​​que prevejam a resposta a terapêuticas dirigidas pode melhorar os resultados dos doentes e otimizar a seleção do tratamento.

Além disso, a crescente colaboração, fusão e aquisição entre os participantes do mercado irá ampliar as oportunidades lucrativas para os participantes do mercado no período de previsão de 2023 a 2030. Além disso, o número crescente de participantes no mercado irá expandir ainda mais a taxa de crescimento do mercado no futuro. 

Restrição/Desafio

• Toxicidade e efeitos secundários

Although targeted therapies are designed to be more selective, they can still have side effects. Off-target effects or on-target but unintended effects can lead to toxicity and adverse reactions. Managing the balance between efficacy and tolerability remains an ongoing challenge.

On the other hand, the high cost associated with product manufacturing is expected to obstruct market growth. Also, the supply chain industry disruption can challenge the market’s growth. Also, lack of favorable reimbursement scenarios, technology penetration in the developing economies, and lack of suitable infrastructure are projected to challenge the market in the forecast period of 2023-2030.

This global small molecule targeted cancer therapy market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global small molecule targeted cancer therapy market contact Data Bridge Market Research for an Analyst Brief, our team will help you make an informed market decision to achieve market growth.

Recent Developments

• In 2021, Roche received accelerated FDA approval for Rozlytrek (entrectinib) as a treatment for certain types of solid tumors with NTRK gene fusions
• In 2021, Novartis received FDA approval for Tabrecta (capmatinib) as a targeted therapy for metastatic non-small cell lung cancer (NSCLC) with MET exon 14 skipping mutations

Global Small Molecule Targeted Cancer Therapy Market Scope

The global small molecule targeted cancer therapy market is segmented on the basis of type, application, and end users. The growth amongst these segments will help you analyze meager growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

• Small Molecules
• Small Molecule Drug Conjugates
• Monoclonal Antibodies

Application

• Lymphoma
• Melanoma
• Multiple Myeloma
• Breast Cancer
• Prostate Cancer
• Other Cancers

End User

• Hospitals
• Cancer and Radiation Therapy Centers
• Clinics

Global Small Molecule Targeted Cancer Therapy Market Regional Analysis/Insights

The global small molecule targeted cancer therapy market is analyzed, and market size insights and trends are provided by product, application, and end-user as referenced above.

The countries covered in the global small molecule targeted cancer therapy market report are U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E, Egypt, Israel, Rest of Middle East and Africa.

North America is expected to dominate the market due to factors including rising healthcare costs, increased R & D, and trending technological advancements.

Asia-Pacific is expected to witness the fastest growth during the forecast period of 2023 to 2030 because of the rising strategic initiatives by the key market players and favorable government initiatives in the region.

The country section of the report also provides individual market impacting factors and changes in market regulation that impact the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of Europe brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

The global small molecule targeted cancer therapy market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment, installed base of different kind of products for Small Molecule Targeted Cancer Therapy market, impact of technology using life line curves and changes in healthcare regulatory scenarios and their impact on the Small Molecule Targeted Cancer Therapy market. The data is available for the historic period 2015-2021

Competitive Landscape and Small Molecule Targeted Cancer Therapy Market Share Analysis

The global small molecule targeted cancer therapy market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to the market.

Some of the major players operating in the global small molecule targeted cancer therapy market are:

• Boehringer Ingelheim International GmbH (Germany)
• Abbott Laboratories. (U.S.)
• CYTOKINETICS, INC.(U.S.)
• Bayer AG (Germany)
• GlaxoSmithKline plc. (UK)
• AstraZeneca (UK)
• AVEO Pharmaceuticals, Inc. (U.S.)
• (EUA)
• (Israel)
• (EUA)
• Allergan (Irlanda)
• Merck Sharp & Dohme Corp.
• (EUA)
• F. Hoffmann-La Roche Ltd (Suíça)
• Novartis AG (Suíça)
• Sanofi (França)
• Amgen Inc.
• (EUA)
• Eli Lilly and Company (EUA)
• Bausch Health (Canadá)

SKU-59146